D. Western Therapeutics Institute Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Yuichi Hidaka

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	15.9yrs
Eigentum des Geschäftsführers	7.7%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	10.6yrs

Jüngste Management Updates

Recent updates

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

May 23

Geschäftsführer

Yuichi Hidaka (51 yo)

15.9yrs

Amtszeit

Mr. Yuichi Hidaka has been President of D.Western Therapeutics Institute, Inc.(DWTI) since December 2008 and serves as its Chief Executive Officer. Mr. Hidaka serves as a Director at Actual Eyes Inc. He se...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yuichi Hidaka	President	15.9yrs	keine Daten	7.69% ¥ 286.4m
Sayako Matsubara	CFO & Director	1.7yrs	keine Daten	0.015% ¥ 548.9k
Yoshiyuki Yamakawa	Independent Outside Director	14.7yrs	keine Daten	0.047% ¥ 1.8m
Eisaku Nakamura	Independent Outside Director	6.6yrs	keine Daten	0.00026% ¥ 9.7k
Masaaki Suzuki	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Tasuku Honjyo	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Masato Shibuya	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Arata Uemura	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Anthony Means	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Walter Chazin	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Yasuhiko Ito	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Yasumi Uchida	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

10.6yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 4576Die Vorstandsmitglieder sind sehr erfahren ( 10.6 ).

D. Western Therapeutics Institute Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

Recent updates

D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023)

New major risk - Share price stability

New minor risk - Shareholder dilution

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

First quarter 2024 earnings released: JP¥9.96 loss per share (vs JP¥3.11 loss in 1Q 2023)

New minor risk - Shareholder dilution

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2024 Results on May 13, 2024

D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

Full year 2023 earnings released: JP¥25.55 loss per share (vs JP¥14.47 loss in FY 2022)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: JP¥6.11 loss per share (vs JP¥3.94 loss in 3Q 2022)

New minor risk - Share price stability

D. Western Therapeutics Institute, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Second quarter 2023 earnings released: JP¥4.73 loss per share (vs JP¥3.03 loss in 2Q 2022)

D. Western Therapeutics Institute, Inc. to Report Q2, 2023 Results on Aug 10, 2023

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

First quarter 2023 earnings released: JP¥3.11 loss per share (vs JP¥0.71 loss in 1Q 2022)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023

Full year 2022 earnings released: JP¥14.47 loss per share (vs JP¥5.05 loss in FY 2021)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Insufficient new directors

Third quarter 2022 earnings released: JP¥3.94 loss per share (vs JP¥0.65 loss in 3Q 2021)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: JP¥3.03 loss per share (vs JP¥1.40 loss in 2Q 2021)

D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc.

D. Western Therapeutics Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2022 Results on May 12, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

D. Western Therapeutics Institute, Inc. to Report Q1, 2021 Results on May 13, 2021

D. Western Therapeutics Institute, Inc. to Report Q3, 2020 Results on Nov 12, 2020

D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

Geschäftsführer

Amtszeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter